Suscribirse

Early lung ultrasound assessment for the prognosis of patients hospitalized for COVID-19 pneumonia. A pilot study - 04/06/21

Doi : 10.1016/j.resmer.2021.100832 
Alexandros Kalkanis, MD PhD 1, , Els Wauters, MD PhD 1, Dries Testelmans, MD PhD 1, Jonas Yserbyt, MD PhD 1, Natalie Lorent, MD PhD 1, Zafeiris Louvaris, PhD 1, 2, Laurent Godinas, MD PhD 1, Pierre Van Mol, MD 1, 3, Joost Wauters, MD PhD 4, Mavroudis Eleftheriou, MD PhD 5, Christophe Dooms, MD PhD 1
1 Department of Respiratory Diseases, University Hospitals KU Leuven, Leuven, Belgium 
2 Faculty of Movement and Rehabilitation Sciences, Department of Rehabilitation Sciences, Research Group for Rehabilitation in Internal Disorders, KU Leuven, Belgium 
3 Laboratory of Translational Genetics, VIB - KU Leuven Center for Cancer Biology, Herestraat 49 b912, 3000 Leuven, Belgium 
4 Department of Internal Medicine, University Hospitals KU Leuven, Leuven, Belgium 
5 Aristotle University of Thessaloniki, Department of Mathematics, Thessaloniki, Greece 

Corresponding author: Department of Respiratory Diseases University Hospitals KU Leuven, Herestraat 49, B-3000 Leuven, BelgiumDepartment of Respiratory Diseases University Hospitals KU LeuvenHerestraat 49LeuvenB-3000Belgium

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

En prensa. Manuscrito Aceptado. Disponible en línea desde el Friday 04 June 2021
This article has been published in an issue click here to access

Abstract

Objective: SARS CoV-2 is an epidemic viral infection that can cause mild to severe lung involvement. Newly apprehended knowledge on thoracic imaging abnormalities and the growing clinical experience on the evolution of this disease make the radiographic follow-up of hospitalized patients relevant. The value of consecutive bedside lung ultrasonography in the follow-up of hospitalized patients with SARS CoV-2 pneumonia and its correlation with other clinical and laboratory markers needs to be evaluated.

Methods: We assessed 39 patients [age: 64 y(60.1 - 68.7)] with confirmed SARS CoV-2 pneumonia. 24 patients were hospitalized until the follow-up test, 9 were discharged early and 6 required a transfer to critical care unit. Two ultrasound scans of the lung were performed on day 1 and 4 of patients´ hospitalization. Primary endpoint was the magnitude of association between a global lung ultrasound score (LUS) and clinical and laboratory markers. Secondary endpoint was the association between the evolution of LUS with the corresponded changes in clinical and laboratory outcomes during hospitalization period.

Results: LUS score on admission was higher among the deteriorating patients and significantly (p=0.038-0.0001) correlated (Spearman’s rho) with the levels of C-reactive protein (0.58), lymphocytes (-0.33), SpO2 (-0.48) and oxygen supplementation (0.48) upon admission. The increase in LUS score between the two scans was significantly correlated (0.544, p=0.006) with longer hospital stay.

Conclusion: Lung ultrasound assessment can be a useful as an imaging modality for SARS CoV-2 patients. Larger studies are needed to further investigate the predictive role of LUS in the duration and the outcome of the hospitalization of these patients.

El texto completo de este artículo está disponible en PDF.

Keywords : biomarkers, COVID-19, prognosis, ultrasonography



© 2021  SPLF and Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.